Giraudo Bryan, COO/CFO, has engaged in 25 reported transactions across two companies—Gossamer Bio (GOSS) and Protagonist Therapeutics (PTGX)—with no recorded dollar value for buys or sells. The filings show a pattern of stock awards (code "A") and derivative transactions (code "D"), primarily concentrated in GOSS. On March 19, 2026, Bryan executed 10 stock awards and 10 derivative transactions in GOSS, all with no disclosed monetary value, suggesting these were likely equity grants or option exercises rather than open-market purchases or sales. Earlier in 2026, Bryan received additional awards in both GOSS and PTGX on January 2, followed by a single GOSS award on October 1, 2025.
The absence of any market purchases or sales in the filings indicates Bryan’s activity has been limited to equity compensation-related transactions rather than discretionary trading. The repeated awards in GOSS, particularly the cluster in March 2026, point to ongoing equity-based compensation tied to his executive role. While the lack of dollar values makes it difficult to assess the economic weight of these transactions, the filings reflect a passive accumulation of shares through corporate grants rather than an active trading strategy. No sales or open-market buys have been reported, leaving no clear directional bias in Bryan’s holdings.
AI-assisted summary